Probatebeta
Target

GUCY1B2

Putative guanylate cyclase soluble subunit beta-2

As of the edition of 20 October 2026, GUCY1B2 (putative guanylate cyclase soluble subunit beta-2, UniProt O75343) has 14 drugs tested at it and 31 companies on the list, 0 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
O75343
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Disease areas
Heart and blood vessels; Lungs and airways; Infections; Urinary and reproductive; Pregnancy and women's health; Nervous system; Cancer; Inherited and neonatal
Registered trials of its drugs
507

Drugs at this target

StatusCount
Marketed9
Active2
Went quiet1
Stopped2
Total14
DrugStatusFurthest phaseUS protection
Nitric oxideMarketedPhase 4Ends 2029
NitroglycerinMarketedPhase 4none listed
Methylene blue cationMarketedPhase 4Ends 2027
RiociguatMarketedPhase 4Ends 2034
NitroprussideMarketedPhase 4none listed
VericiguatMarketedPhase 4Ends 2032
Isosorbide mononitrateMarketedPhase 4none listed
Isosorbide dinitrateMarketedPhase 4none listed
PraliciguatActivePhase 2none listed
OlinciguatWent quietPhase 2none listed
AtaciguatActivePhase 3none listed
CinaciguatStoppedPhase 2none listed

12 of 14 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route B5
Engaged13
Undetermined13
Total on the list31
Three companies on route A or B, with the route only
CompanyRoute
Merck & Co.Route B
RocheRoute B
Dr. Reddy'sRoute B

The other 28 companies at GUCY1B2

In the product

31 companies in all; 28 are not named here, and no score is.

See the 31 companies at GUCY1B2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in heart and blood vessels

Companies holding approvals at GUCY1B2